Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...

Zymo’s Quick DNA/RNA Viral MagBead Kit was automated using Analytik Jena’s Cybio FeliX pipetting robot. The CyBio FeliX ...